Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DRALZINE vs ALDORIL 15
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Dralzine is a direct-acting arteriolar vasodilator that relaxes vascular smooth muscle, leading to decreased systemic vascular resistance and afterload. The exact molecular mechanism is not fully elucidated but involves inhibition of calcium influx and interference with the contractile process.
Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brainstem, decreasing peripheral vascular resistance and blood pressure. Hydrochlorothiazide is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, reducing plasma volume and cardiac output.
Essential hypertension (off-label),Hypertensive crisis (off-label)
Hypertension
Oral: 50-100 mg twice daily; maximum 200 mg/day.
1 tablet (hydrochlorothiazide 15 mg, methyldopa 250 mg) orally twice daily; increase as needed up to 2 tablets twice daily.
Terminal elimination half-life is 2-5 hours in patients with normal renal function; prolonged to 10-20 hours in renal impairment.
Terminal half-life: 12–17 hours; clinical context: steady-state achieved within 2–3 days; effect persists 12–24 hours
Primarily hepatic via N-acetyltransferase (NAT2); exhibits polymorphic acetylation. Metabolites include hydralazine pyruvate hydrazone and other hydrazone derivatives.
Methyldopa is metabolized in the liver via conjugation and O-methylation; active metabolites include methyldopamine and methylnorepinephrine. Hydrochlorothiazide is not significantly metabolized and is excreted unchanged in urine.
Primarily renal (70-90% as unchanged drug and metabolites); biliary/fecal excretion accounts for <10%.
Renal: ~70% unchanged; biliary/fecal: ~30% as metabolites
85-90%, primarily to albumin.
~90%, primarily to albumin
1.5-2.0 L/kg; indicates extensive tissue distribution, exceeding total body water.
2–4 L/kg; clinical meaning: extensive tissue distribution, concentrating in vascular smooth muscle
Oral: 30-50% due to first-pass metabolism.
Oral: 50–60% (extensive first-pass metabolism)
GFR 10-50 m L/min: 50 mg twice daily; GFR <10 m L/min: 50 mg once daily.
GFR 30-50 m L/min: maximum 1 tablet twice daily. GFR <30 m L/min: avoid use.
Child-Pugh A: no adjustment; Child-Pugh B: 50 mg twice daily; Child-Pugh C: avoid use.
Child-Pugh A: caution, reduce dose. Child-Pugh B: avoid. Child-Pugh C: contraindicated.
1-2 mg/kg/day divided every 12 hours; maximum 5 mg/kg/day.
Not recommended for pediatric use; safety in children under 12 years not established.
Initiate at 25 mg twice daily; titrate slowly to avoid hypotension.
Start with 1 tablet once daily; monitor for hypotension and electrolyte imbalance. Reduce initial dose by 50%.
None.
None
May induce a lupus-like syndrome, especially in slow acetylators; monitor for symptoms such as arthralgia, fever, and rash.,May cause drug-induced autoimmune hepatitis.,Can precipitate angina or myocardial infarction in patients with coronary artery disease.,Risk of hypotension and reflex tachycardia.
Sedation, usually transient; may impair ability to drive or operate heavy machinery.,Positive Coombs test with hemolytic anemia (rare); monitor hematocrit and Coombs test.,Hepatotoxicity (hepatic necrosis) with fever, jaundice; discontinue if liver abnormalities occur.,Fluid and electrolyte imbalance (hypokalemia, hyponatremia, hypercalcemia) due to thiazide.,May precipitate gout in hyperuricemic patients.,May exacerbate systemic lupus erythematosus.
Hypersensitivity to hydralazine or components,Coronary artery disease (relative contraindication due to risk of myocardial ischemia),Mitral valve rheumatic heart disease (relative),Idiopathic lupus erythematosus
Active hepatic disease (e.g., acute hepatitis, cirrhosis),Prior methyldopa therapy associated with liver disorders,Hypersensitivity to methyldopa or hydrochlorothiazide,Anuria,Sulfonamide allergy (cross-sensitivity with thiazides)
DRALZINE should be taken with or without food, but consistent timing is recommended. High-tyramine foods (e.g., aged cheeses, cured meats, fermented products) may increase the risk of hypertensive crisis in patients also taking MAOIs; however, interactions with food are otherwise minimal. Avoid large, high-fat meals as they may affect absorption.
Avoid high-sodium foods as they can reduce antihypertensive efficacy. Thiazides may cause hypokalemia; increase dietary potassium (bananas, orange juice) unless contraindicated. Alcohol may enhance orthostatic hypotension.
First trimester: No evidence of teratogenicity in human studies; however, consider fetal hypotension and impaired uteroplacental perfusion. Second and third trimesters: Risk of fetal hypotension, adverse fetal heart rate patterns, and neonatal adverse effects (hypotension, tachycardia, fluid retention).
First trimester: No increased risk of major malformations based on limited human data; animal studies show no teratogenicity at clinically relevant doses. Second/third trimesters: Fetal and neonatal adverse effects including oligohydramnios, fetal renal dysfunction, skull ossification delay, and hypotension in the neonate. Avoid use after 20 weeks gestation unless no alternative.
Compatible with breastfeeding. M/P ratio not established; drug appears in breast milk in low amounts (<1% maternal dose). No reported adverse effects in infants.
Methyldopa and hydrochlorothiazide are excreted into human milk. M/P ratio for methyldopa is approximately 0.5-1.0; for hydrochlorothiazide, M/P ratio ~2.0. Methyldopa is considered compatible with breastfeeding. Hydrochlorothiazide may suppress lactation and cause neonatal electrolyte disturbances. Use with caution; monitor infant for signs of diuresis or electrolyte imbalance.
No specific dose adjustments required based on pharmacokinetic changes in pregnancy. However, because of increased blood volume, higher doses may be needed to achieve same antihypertensive effect; titrate to target blood pressure.
Pharmacokinetic changes in pregnancy may include increased volume of distribution and enhanced renal clearance. No specific dose adjustment routine is recommended; dosing should be guided by clinical response. Methyldopa starting dose 250 mg twice daily, titrated to effect. Hydrochlorothiazide dose not typically adjusted, but caution due to potential volume depletion.
DRALZINE (hydralazine) is a direct-acting vasodilator used primarily for hypertension, especially in pregnancy (pre-eclampsia). It can cause a drug-induced lupus-like syndrome, especially in slow acetylators; monitor for arthralgias, rash, and positive ANA. Tachycardia is a common reflex response; often co-administered with a beta-blocker. Avoid in patients with coronary artery disease, high-output heart failure, or mitral valve rheumatic heart disease.
Aldoril 15 (methyldopa 250mg + hydrochlorothiazide 15mg) is rarely used due to superior alternatives. Monitor for hepatotoxicity, hemolytic anemia, and lupus-like syndrome. Titrate slowly to avoid sedation. Contraindicated in active liver disease, pheochromocytoma, and anuria.
Take exactly as prescribed; do not skip doses or double up.,You may experience dizziness or lightheadedness, especially when standing up; rise slowly and avoid sudden position changes.,Report any joint pain, rash, fever, or chest pain to your healthcare provider immediately.,Avoid alcohol, which can worsen side effects like dizziness and low blood pressure.,Do not stop taking this medication abruptly; sudden withdrawal can cause a rapid increase in blood pressure.
May cause drowsiness; avoid driving until tolerance develops.,Report unexplained fever, jaundice, or dark urine immediately.,Take at bedtime to minimize sedation.,Avoid sudden discontinuation; follow prescribed tapering schedule.,Use sun protection; thiazides increase photosensitivity.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DRALZINE vs ALDORIL 15, answered by our medical review team.
DRALZINE is a Antihypertensive that works by Dralzine is a direct-acting arteriolar vasodilator that relaxes vascular smooth muscle, leading to decreased systemic vascular resistance and afterload. The exact molecular mechanism is not fully elucidated but involves inhibition of calcium influx and interference with the contractile process.. ALDORIL 15 is a Antihypertensive Combination that works by Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brainstem, decreasing peripheral vascular resistance and blood pressure. Hydrochlorothiazide is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, reducing plasma volume and cardiac output.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DRALZINE and ALDORIL 15 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DRALZINE is: Oral: 50-100 mg twice daily; maximum 200 mg/day.. The standard adult dose of ALDORIL 15 is: 1 tablet (hydrochlorothiazide 15 mg, methyldopa 250 mg) orally twice daily; increase as needed up to 2 tablets twice daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DRALZINE and ALDORIL 15 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DRALZINE is classified as Category C. First trimester: No evidence of teratogenicity in human studies; however, consider fetal hypotension and impaired uteroplacental perfusion. Second and third trimesters: Risk of fet. ALDORIL 15 is classified as Category C. First trimester: No increased risk of major malformations based on limited human data; animal studies show no teratogenicity at clinically relevant doses. Second/third trimesters: . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.